Descovy, Truvada And The Politics Of PrEP

US FDA's advisory committee review of Gilead’s Descovy for pre-exposure prophylaxis of HIV wasn’t exactly free of controversy. But the meeting sure went more smoothly than the first PrEP review seven years ago.

Pre-exposure-PrEP-pill

More from US FDA Performance Tracker

More from Regulatory Trackers